Latest News About Ozempic Side Effects

Here’s the latest on Ozempic side effects based on recent reporting.

• FDA activity and safety signals (2023–2024 into 2026)

  • The FDA has continued to assess safety signals related to GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound, including reports of alopecia, aspiration, and suicidal ideation, and has indicated that regulatory actions could follow a thorough review of data.[1][2]
  • In 2026, CBS News reported that the FDA issued a warning letter to Novo Nordisk for unreported potential adverse events, including deaths and suicidal ideation among patients on semaglutide, underscoring ongoing post-market safety monitoring and compliance enforcement.[3][4]

• Label updates and known adverse events

  • The FDA has updated Ozempic’s label in the past to include information about certain adverse events such as ileus (intestinal obstruction), reflecting evolving real-world safety data.[1]
  • Reports and regulatory reviews continue to explore a range of potential side effects associated with GLP-1 drugs, with agencies weighing regulatory actions as new safety signals emerge.[2][1]

• Industry and public health coverage

  • Healthcare outlets and medical associations have discussed Ozempic-related side effects in the context of broader GLP-1 drug safety, including discussions of rare or serious events and how regulators respond to new information.[5][6]
  • Public resources also reflect ongoing medical discourse about side effects and safety labeling as data accumulate from pharmacovigilance programs and post-marketing surveillance.[7]

• Notable developments

  • A March 2026 CBS CBS News report highlighted that drugmakers were under FDA scrutiny for reporting practices tied to potential Ozempic-related adverse events, illustrating the importance of accurate adverse event reporting in post-market safety oversight.[4][3]

If you’d like, I can:

• Compile a concise, up-to-date summary of the most credible safety signals and their current regulatory status.
• Pull the exact FDA labeling changes and dates for Ozempic and related GLP-1 drugs.
• Provide a consumer-friendly FAQ on what side effects have been observed, what to watch for, and when to contact a clinician.

Would you like me to tailor this to a specific concern (e.g., mental health side effects, GI issues, or reporting requirements)?

Citations:

• FDA safety signals and GLP-1 class review[1]
• FAERS signals and regulatory actions context[2]
• FDA warning to Novo Nordisk about unreported adverse events[3]
• Related reporting on labeling updates and adverse events[4]
• AMA/medical outlets discussion on Ozempic side effects and safety monitoring[6][5]